ABSTRACT Human growth hormone (hGH) and ovine prolactin (oPRL) are both lactogenic as defined by their ability to induce milk-protein synthesis in vitro in the presence of insulin and hydrocortisone. At physiological concentrations, both hGH and oPRL have similar dose-response curves in a mouse mammary gland organ culture system. Binding of "25I-labeled hGH ('2I-hGH) to lactogenic receptors is competed by both hGH and oPRL, and the competition curves are nearly superimposable. Moreover, solubilized membrane proteins bound with either '25I-hGH or '2MI-labeled oPRL show the same sedimentation pattern on sucrose gradients. However, methylation of membrane phospholipids in the presence of the methyl donor S-adenosyl-Lmethionine only increases the binding of "5I-hGH. Bindin of either '25I-oPRL or '25I-labeled bovine growth hormone (15I-bGH) was unaffected. Addition of concanavalin A (Con A) to the membranes decreased binding of "I5-oPRL to the lactogenic site by 80%, whereas 125I-hGH binding was decreased by only 40%, with the binding of '"I-bGH unaffected. However, both hGHand oPRL-bound proteins bind to Con A-Sepharose columns to the same extent. These results suggest that although hGH and oPRL bind to the same lactogenic site with similar affinities and elicit similar biological responses, modification ofmembranes either by phospholipid methylation or by Con A differentially affects the binding of these two hormones.
and oPRL-bound proteins bind to Con A-Sepharose columns to the same extent. These results suggest that although hGH and oPRL bind to the same lactogenic site with similar affinities and elicit similar biological responses, modification ofmembranes either by phospholipid methylation or by Con A differentially affects the binding of these two hormones.
Membrane-associated specific binding proteins or receptors have been implicated in the mode ofaction ofseveral hormones (1, 2) . Thus, it is believed that the sensitivity of a target tissue towards a hormone is regulated by the number and affinity of its binding sites (3) . The number of binding sites on the membranes can be increased either by synthesizing new receptor molecules or by activating preexisting cryptic sites, presumably by changing the membrane environment of the binding proteins. This latter mechanism has been described for modulation of binding of human growth hormone (hGH) to lactogenic hormone binding sites in mammary gland membranes (4) . The number of hGH binding sites was found to increase when the phospholipid composition of isolated membranes was changed by the action ofendogenous transmethylases that convert phosphatidylethanolamine to phosphatidylcholine in situ (4) . Such changes in phospholipid composition have been shown to alter membrane fluidity (5) .
The plant lectin concanavalin A (Con A) is also a membraneactive agent that is known to decrease mobility of membrane proteins (6) (7) (8) (9) . Although Con A does not directly interact with the hormone binding site, it does inhibit prolactin (PRL) binding to target tissues, presumably by causing aggregation of membrane proteins (10, 11) . This, in turn, results in an inhibition of milk secretion (12) .
Because both phospholipid methylation and Con A-induced aggregation affect the membranes without altering their basic bilayer structure, we used these mechanisms ofmembrane perturbation to examine the nature ofthe lactogenic hormone binding site. For these studies, the binding oftwo known lactogenic hormones, hGH and ovine PRL (oPRL), was examined. These two hormones have different primary structures (13) but are believed to bind to the same site with similar affinity constants (14, 15) . The results shown here clearly indicate that although both hGH and oPRL do bind to the same molecular site and have similar biological activities, their binding properties definitely show different sensitivities to membrane alterations due to phospholipid methylation or the action of Con A.
MATERIALS AND METHODS Materials. hGH (HS 243), oPRL (NIH-P-S-12), and bovine growth hormone (bGH; NIH-GH-B18) were gifts from the National Institute of Arthritis, Metabolism, and Digestive Diseases Hormone Distribution Program. S-Adenosyl-L-methionine (AdoMet) was from Sigma; Con A crystallized three times was from Miles-Yeda; Con A-Sepharose (10 mg of Con A per ml of bed volume) was from Pharmacia; Na'25I was from Amersham; porcine zinc insulin was a gift from Eli Lilly; hydrocortisone was from ICN; UDP-galactose and ATP were from Calbiochem; and UDP-[14C]galactose (298 mCi/mmol) was from New England Nuclear.
Iodination of peptide hormones was carried out by a lactoperoxidase method as described (16) . Specific activities upon iodination ranged from 30 to 60 ,Ci/,ug (lCi = 3.7 X 101s becquerels).
All mice were ofthe C3H/HeN strain and were either 10-12 days into their first pregnancy (for organ culture) or 10-12 days lactating after their first pregnancy (for binding studies). All animals were killed by cervical dislocation.
Binding of "5I-Labeled hGH and "I5-Labeled oPRL to Isolated Membranes. Preparation of membranes and binding of 125I-labeled hGH (125I-hGH) or 125I-labeled oPRL (125I-oPRL) were as described (4 
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Unless otherwise stated, the nonspecific binding was determined by the addition of 500 ng of unlabeled hormone to 0.5 ml of reaction mixture per tube. Nonspecific binding was subtracted from total binding to yield specific binding. The nonspecific binding represents about 10% of the total binding to liver and 40-50% in the mammary gland.
Organ Culture of Mammary Gland and Measurement of Lactose Synthetase Activity. Organ culture ofabdominal mammary glands was performed as described (17) . Pooled explants prepared from the tissue of several mice were cultured in serum-free medium 199 (GIBCO) containing insulin (5 ,ug/ ml), hydrocortisone (1 ,ug/ml), and various concentrations of unlabeled hGH or oPRL. After 48 hr. lactose synthetase activity in the mammary tissue was determined as described (18) . either '25I-hGH or '25I-oPRL (2-5 ng) in a total volume of [1] [2] ml. The binding reaction was stopped by the addition of3.0 ml of cold lactogenic binding buffer. The membranes were collected by centrifugation at 1500 x g for 20 min and washed once with 5.0 ml of cold lactogenic binding buffer. The membranes were then solubilized for 30 min at room temperature either in 50 mM Tris-HCl, pH 7.5/1% Triton X-100 or in 50 mM Tris'HCl, pH 7.5/1 mM CaCl2/1 mM MgCl2/1% Triton X-100 (15, 19) at a final concentration of 1-3 mg ofmembrane proteins per ml. The suspension was then centrifuged at 200,000 X g for 60 min. In either buffer, 50-70% of the radioactivity was recovered in the soluble fraction of which over 90% remained bound to receptors. Increasing the Triton X-100 concentration did not increase the efficiency of extraction.
Sucrose Gradient Centrifugation. Solubilized "2I-labeled hormone-receptor complex (0.5 ml) was placed on the top of a 5-20% linear sucrose gradient (11.0 ml) in 50 mM Tris HCl, pH 7.5/0.1% Triton X-100. The gradients were spun for 20 hr at 40C at 40,000 rpm in a SW 41 rotor with a Beckman untracentrifuge. Fractions (-0.35 ml) were collected from the bottom of the tube, and radioactivity was determined for each fraction in a Packard Autogamma spectrometer.
Affinity Chromatography on Con A-Sepharose. One milliliter of Con A-Sepharose suspension (=5 mg of Con A) packed in a 0.5 X 3.0 cm column was washed with 10.0 ml of Con A binding buffer (50 mM Tris HCl, pH 7.5/1 mM MgCl2/1 mM CaCI2/0. 1% Triton X-100). Membranes treated with the 125I-labeled hormone were solubilized in the Tris/Ca/Mg/Triton X-100 buffer and then placed on the column, which was washed with Con A binding buffer. The eluate was then passed through the column two more times to ensure quantitative binding (unpublished data). The bound material was then eluted with 0.3 M a-methyl mannoside/0.1% Triton X-100. The chromatography was performed at room temperature. RESULTS Both oPRL and hGH have been shown to have lactogenic properties and to bind to lactogenic receptors on membranes of target tissues (14, 15, 20, 21) . From competition binding curves, it appears that they may bind to the same site. hGH also has been shown to have somatogenic properties (22) . The level of lactogenic and somatogenic potency can vary with the preparation ofhormone used. Therefore, we examined the hGH and oPRL preparations used in these binding studies to ascertain their biological potency as lactogenic agents.
The ability of hGH and oPRL to induce lactose synthetase activity in explants of mammary glands from midpregnant mice is shown in Fig. 1 . Both hGH and oPRL stimulate lactose synthetase activity when added to cultures in the presence of insulin and hydrocortisone. At low concentrations, both hor- mones gave similar responses. However, at higherconcentrations, above physiological, this preparation ofhGH was more effective than was the oPRL preparation. This observation is similar to reports of others (23, 24) . Clearly, however, both hGH and oPRL are lactogenic and have similar biological potency within the physiological range.
Similarly, binding of both hormones was examined with membranes prepared from target tissues from lactating mice. Generally, more binding is observed with liver membranes than with membranes prepared from mammary glands, although similar results were obtained for both tissues. Fig. 2 shows the results obtained for the hepatic binding sites. Both '25I-hGH and 125I-oPRL at fixed concentrations were competed with various concentrations ofeither ofthe unlabeled hormones. Overlapping competition curves were observed when '25I-hGH was competed with either unlabeled hGH or oPRL. These curves were very similar to that obtained when '25I-oPRL was com- peted with oPRL, confirming that both hGH and oPRL bind to the same site with similar affinities. bGH did not effectively compete for binding by either hormone (data not shown).
Further evidence that both hGH and oPRL bind to the same molecular species is given in Fig. 3 . 125I-Labeled hormone-receptor complexes were solubilized with Triton X-100 and then analyzed on 5-20% sucrose gradients. Both the 125I-hGHreceptor complex and the 125I-oPRL-receptor complex sedimented to the same extent in the gradients giving a single major peak. The smaller peak seen near the top of the gradients containing the 125I-oPRL-receptor complex was identified as free oPRL that is known to aggregate in the presence ofTriton X-100 (15, 25) . Free hGH sediments at the top ofthe gradient. These data, taken together, show that both hGH and oPRL bind to the same molecular species in the target tissue membranes and subsequently elicit a similar biological response. We have shown that methylation of phosphatidylethanolamine to form phosphatidylcholine by the addition of AdoMet to isolated lactating mammary gland membranes enhances 125I-hGH binding to lactogenic receptors (4) . Table 1 shows the effect ofaddition ofAdoMet on hGH and oPRL binding to isolated liver and mammary gland membranes. Significant increases in 12'I-hGH binding to both membranes were observed. This enhancement of binding by AdoMet was the result of an increase in total binding with no change in nonspecific binding (4) . In contrast, little or no effect of AdoMet was observed when 125i-oPRL was used as the probe for lactogenic receptors. In addition, no effect on "2I-labeled bGH ('mI-bGH) binding was observed with either membrane preparation (data not shown). AdoMetfor 30 min at room temperature. Subsequently either 1251-hGH or '25I-oPRL was added to the reaction tubes, and binding was carried out as described. Nonspecific binding was determined for each concentration of AdoMet by addition of 500 ng of unlabeled oPRL to the reaction. Specific binding was obtained by subtracting nonspecific from total binding.
The difference observed between hGH and oPRL binding is not unique to membrane alterations resulting from phospholipid methylation. The membrane-active agent Con A has been shown to inhibit PRL binding to target tissue membranes, whereas succinylated Con A does not (10) . This is believed to occur through decreased mobility or aggregation of receptors by the native tetravalent Con A. Fig. 4 shows the effect of Con A on hGH and oPRL bindingto liver membranes. Although Con A inhibited specific oPRL binding by about 80%, only 40-50% inhibition of specific hGH binding was observed. This quantitative difference was seen in all such experiments and is a result in a change in total binding with no change in nonspecific binding. The results oftwo separate experiments with different membrane pools are in Fig. 4 A and ranging from 0 to 500 Ag/ml (data not shown).
The lactogenic receptor complex has a Con A-binding site distinct from the hormone-binding site (unpublished data). However, the difference in response is not due to the inability of Con A to bind to the receptor to the same extent in the presence of the two different hormones. This is shown in studies with a Con A-Sepharose affinity column. '"I-Labeled hormone-receptor complex was solubilized from liver membranes and then passed through a Con A-Sepharose column. Table 2 shows that both '"I-hGH-receptor and 125I-oPRL-receptor complexes bound to the affinity column to the same extent.
However, 125I-bGH-receptor complex did not bind at all. These data show that the.difference between Con A inhibition ofhGH binding and oPRL binding is not due to differential binding of the lectin to somatogenic vs. lactogenic sites.
DISCUSSION
hGH has been shown to have both lactogenic and somatogenic properties (22) . On the other hand, PRL is essentially lactogenic. Previous studies have shown that hGH predominantly binds to lactogenic sites (14, 15) . However, some workers have been able to distinguish somatogenic and lactogenic sites for hGH (26, 27) .
From the experiments presented here, it is clear that hGH and oPRL bind to the same molecular sites in the target tissue membranes and subsequently elicit similar biological responses. Failure to detect a separate binding component for hGH may be due to two reasons: (i) the presence of predominantly lactogenic sites over somatogenic sites in liver and mammary gland membranes from lactating mice and (ii) the similarity of the physical characteristics of the sites, making them indistinguishable by the criteria used here. This latter possibility seems less likely because differences in the molecular size of lactogenic and somatogenic receptors have been reported (28) . In addition, studies by Waters and Friesen (29) with antisera against a partially purified growth hormone receptor have shown that the two types of receptors are immunologically distinct. Finally, that lactogenic receptors are distinct from somatogenic receptors is demonstrated by the ability of the former, but not the latter, to bind to Con A (see Table 2 ).
Endogenous phospholipid methylation by the methyl donor AdoMet and Con A-induced protein aggregations were used to cause changes in the membranes without altering the bilayer structure. AdoMet stimulated '`I-hGH binding to lactogenic sites, whereas no change was observed for 125I-oPRL binding.
On the other hand, Con A inhibited oPRL binding by 80%, whereas hGH binding was reduced by only 40-50% despite the fact that both hormone-receptor complexes bind to Con A to the same extent. Studies with bGH binding indicate that the decreased inhibition of hGH binding is probably not due to binding of that hormone to somatogenic sites.
Formation ofthe hormone-receptor complex depends on the molecular conformation ofthe receptor within the membranous environment and the three-dimensional geometry of the hormone, which is dictated by its primary structure. Because there is a difference in the primary structure of hGH and oPRL (13) and different forms ofhGH and PRL (20, 21) , it follows that the environmental requirements for maximum binding may not be the same for the two hormones. The system described here is shown to offer an effective tool to study such requirements.
